Source: Annual Congress 2005 - Cystic fibrosis: of exercise, aerosol and more
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Casciaro, A. De Alessandri, F. Lugani, E. Poggi, C. Gardella, G. Manno, L. Giampietri, M. Mentasti, R. Lorini (Genoa, Italy). Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection. Eur Respir J 2005; 26: Suppl. 49, 3945

Member's Comments

No comment yet.

Related content which might interest you: Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020 Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model Source: Eur Respir J 2007; 29: 965-968 Year: 2007 An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005 Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response Source: Eur Respir J 2007; 30: 1167-1172 Year: 2007 Dental units as infection sources of Pseudomonas aeruginosa Source: Eur Respir J 2008; 32: 1122-1123 Year: 2008 The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 Can LCI predict new Pseudomonas aeruginosa colonization among CF patients?> Source: International Congress 2017 – What is the future for paediatric respiratory physiology and sleep? Year: 2017 The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Source: Eur Respir J 2014; 44: 794-797 Year: 2014